Published in Genomics and Genetics Weekly, June 16th, 2006
Study 1: Recent research from the People's Republic of China has reported on the clarification of hepatocellular carcinoma (HCC) prodrug cell killing activity.
"Gene therapy with nonviral vectors using the suicide gene/prodrug activating system of herpes simplex virus type-1 thymidine kinase (HSV1-TK)/ganciclovir (GCV) is inefficient in killing malignant tumor cells due to two major factors: (a) an unsatisfactory bystander effect; (b) short-lived expression of the protein," wrote L.M. Cao and colleagues, Jiangsu Institute of Parasitic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.